培菲康对肝硬化血浆内毒影响的研究

Experimental and clinical study of BIFICO on plasma endotoxin in rats and patients with liver cirrhosis

目的 探讨益生菌制剂培菲康治疗肝硬化内毒素血症的作用机制。方法 采用大鼠肝硬化模型,其中治疗组予以培菲康液每天灌胃治疗,共8周,检测治疗组及对照组血浆内毒指标;并选取70例肝硬化Child-Pugh分级为B级的患者,其中治疗组口服培菲康胶囊(每次2粒,每天3次) 3周,观察治疗前后血浆内毒素变化。结果 培菲康治疗组的肝硬化大鼠及患者血浆内毒素均明显低于对照组( P<0 .0 5 )。结论 培菲康能明显降低肝硬化患者血浆内毒素水平。

Objective To investigate the effect of Bifico capsule on the levels of plasma endotoxin in rats and patients with liver cirrhosis.Methods 44 wistar rats were induced into live cirrhosis models by injecting CCl 4 every 3 days for 8 weeks.70 patients with cirrhosis of Child pugh B stage wee observed,35 patients were treated by Bifico capsule(2 capsules,triple daily) orally for three weeks.Plasma endotoxin was detected before and after the therapy.Result The levels of endotoxin in the treatment groups were significantly lower than those in control group( P <0 05).Conclusion Bifico could reduce the level of endotoxin with liver cirrhosis,it could be used for routine auxillary therapy on the liver cirrhosis.